Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-၁.၉၂%
၁,၀၉၂.၇၄
-၂၁.၄၀
-၁.၉၂%
၁,၁၁၄.၁၄၁,၁၁၉.၃၉၁,၁၂၁.၁၉၁,၀၉၂.၂၂
SIXC
Communications
SIXC
Communications
SIXC
-၀.၀၄%
၆၁၃.၃၆
-၀.၂၄
-၀.၀၄%
၆၁၃.၆၀၆၁၃.၆၀၆၁၇.၈၀၆၁၁.၆၅
SIXE
Energy
SIXE
Energy
SIXE
-၁.၈၂%
၁,၁၇၆.၇၉
-၂၁.၇၇
-၁.၈၂%
၁,၁၉၈.၅၆၁,၁၈၈.၄၆၁,၁၈၈.၄၆၁,၁၅၉.၅၆
SIXI
Industrials
SIXI
Industrials
SIXI
-၁.၆၂%
၁,၇၅၅.၅၄
-၂၈.၉၁
-၁.၆၂%
၁,၇၈၄.၄၅၁,၇၈၈.၉၅၁,၇၉၂.၈၃၁,၇၄၉.၈၉
SIXM
Financials
SIXM
Financials
SIXM
-၀.၅၇%
၆၃၅.၁၅
-၃.၆၄
-၀.၅၇%
၆၃၈.၇၉၆၃၈.၃၇၆၄၁.၇၂၆၃၃.၇၆
SIXR
Staples
SIXR
Staples
SIXR
-၀.၂၉%
၈၄၈.၀၁
-၂.၄၉
-၀.၂၉%
၈၅၀.၅၀၈၄၈.၉၀၈၅၁.၀၇၈၃၉.၅၂
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-၀.၈၃%
၂၁၇.၈၆
-၁.၈၃
-၀.၈၃%
၂၁၉.၆၉၂၁၉.၆၉၂၁၉.၆၉၂၁၆.၈၉
SIXT
Technology
SIXT
Technology
SIXT
-၀.၂၀%
၃,၄၁၇.၃၅
-၆.၈၄
-၀.၂၀%
၃,၄၂၄.၁၉၃,၄၂၉.၁၈၃,၄၆၃.၃၃၃,၃၉၈.၀၈
SIXU
Utilities
SIXU
Utilities
SIXU
-၁.၃၄%
၉၁၃.၃၆
-၁၂.၄၀
-၁.၃၄%
၉၂၅.၇၆၉၂၂.၇၇၉၂၃.၉၉၉၁၁.၂၂
SIXV
Health care
SIXV
Health care
SIXV
-၀.၄၈%
၁,၄၆၂.၃၈
-၇.၀၂
-၀.၄၈%
၁,၄၆၉.၄၀၁,၄၆၈.၉၆၁,၄၇၃.၁၈၁,၄၅၇.၈၆
SIXY
Discretionary
SIXY
Discretionary
SIXY
-၀.၀၆%
၂,၄၂၃.၁၄
-၁.၄၈
-၀.၀၆%
၂,၄၂၄.၆၂၂,၄၃၈.၂၃၂,၄၄၆.၆၃၂,၄၁၂.၄၈
TRDA:NASDAQ
Entrada Therapeutics Inc
၆.၈၅ US$
-၅၇.၂၇%
(-၉.၁၈) 1D
၆.၇၈ US$
-၁.၀၂% (-၀.၀၇၀)
After hours
Closed: မေ ၇, GMT-၄ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRDA...
Open
၆.၈၂ US$
High
၇.၈၉ US$
Low
၅.၇၃ US$
Mkt. cap
၂၆.၅၉ ကုဋေ
Avg. vol.
၂.၀၂ သိန်း
Volume
၀.၀၀
52-wk high
၁၆.၄၅ US$
52-wk low
၄.၉၃ US$
EPS
-၃.၄၇ US$
Beta
-၀.၀၉
Shares outstanding
၃.၈၈ ကုဋေ
No. of employees
၁၅၂
News stories
From sources across the web
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၄ နာရီ
Entrada Therapeutics (TRDA) Q1 Revenue Slump Tests High Growth Narratives
Benzinga
Benzinga
·
ပြီးခဲ့သည့် ၁၁ နာရီ
Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why
Quiver Quantitative
Quiver Quantitative
·
ပြီးခဲ့သည့် ၁၄ နာရီ
$TRDA stock is down 55% today. Here's what we see in our data.
Seeking Alpha
Seeking Alpha
·
ပြီးခဲ့သည့် ၁၄ နာရီ
Entrada plunges on trial data for Duchenne drug (TRDA:NASDAQ)
About Entrada Therapeutics Inc
CEO-
Employees၁၅၂
Founded၂၀၁၆
Headquartersဘော့စတွန်မြို့, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
၂၀၂၅ မတ်
၂၀၂၅ ဇွန်
၂၀၂၅ စက်
၂၀၂၅ ဒီ
Revenue
၂.၀၆ ကုဋေ
၁.၉၅ သန်း
၁.၆၁ သန်း
၁.၃၀ သန်း
Cost of goods sold
၃.၂၁ ကုဋေ
၃.၇၉ ကုဋေ
၃.၈၄ ကုဋေ
၃.၂၃ ကုဋေ
Cost of revenue
၃.၂၁ ကုဋေ
၃.၇၉ ကုဋေ
၃.၈၄ ကုဋေ
၃.၂၃ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁.၀၃ ကုဋေ
၁.၀၉ ကုဋေ
၁.၀၃ ကုဋေ
၉.၃၅ သန်း
Operating expense
၁.၀၃ ကုဋေ
၁.၀၉ ကုဋေ
၁.၀၃ ကုဋေ
၉.၃၅ သန်း
Total operating expenses
၄.၂၃ ကုဋေ
၄.၈၈ ကုဋေ
၄.၈၇ ကုဋေ
၄.၁၆ ကုဋေ
Operating income
-၂.၁၈ ကုဋေ
-၄.၆၈ ကုဋေ
-၄.၇၁ ကုဋေ
-၄.၀၃ ကုဋေ
Other non operating income
-
-
-
-
EBT including unusual items
-၁.၇၃ ကုဋေ
-၄.၂၉ ကုဋေ
-၄.၃၅ ကုဋေ
-၃.၉၁ ကုဋေ
EBT excluding unusual items
-၁.၇၃ ကုဋေ
-၄.၂၉ ကုဋေ
-၄.၃၅ ကုဋေ
-၃.၇၂ ကုဋေ
Income tax expense
-
၁.၇၈ သိန်း
၆.၅၄ သိန်း
၉.၂၀ သောင်း
Effective tax rate
-
-၀.၄၁%
-၁.၅၀%
-၀.၂၄%
Other operating expenses
-
-
-
-
Net income
-၁.၇၃ ကုဋေ
-၄.၃၁ ကုဋေ
-၄.၄၁ ကုဋေ
-၃.၉၂ ကုဋေ
Net profit margin
-၈၄.၃၉%
-၂,၂၁၀.၄၁%
-၂,၇၃၄.၄၅%
-၃,၀၁၄.၉၃%
Earnings per share
-၀.၄၂
-၁.၀၄
-၁.၀၆
-၀.၉၄
Interest and investment income
၄.၄၄ သန်း
၃.၉၂ သန်း
၃.၅၇ သန်း
၃.၁၄ သန်း
Interest expense
-
-
-
-
Net interest expenses
၄.၄၄ သန်း
၃.၉၂ သန်း
၃.၅၇ သန်း
၃.၁၄ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၂.၀၈ ကုဋေ
-၄.၅၈ ကုဋေ
-၄.၅၈ ကုဋေ
-၃.၉၄ ကုဋေ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more